Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%

HOUSTON, April 8, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.

The release as fetched from its publisher. moleculin.com ↗